Targanta Therapeutics (NASDAQ:[[ticker:TARG]]) has released detailed data from its Phase 2 study of its antibiotic oritavancin in single or infrequent doses, showing that the fewer doses were as safe and effective as a three-to-seven day course of therapy, according to the Cambridge, MA-based firm. Luke wrote earlier this month about Targanta’s hoped-for FDA approval of oritavancin—which is intended to treat skin infections, including those cause by antibiotic-resistant bugs such as MRSA—this year.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
